Therapeutic improvement of a stroma-targeted crad by incorporating motives responsive to the melanoma microenvironment

Journal of Investigative Dermatology

Volumn 133, Issue 11, 2013, Pages 2576-2584

  Viale, Diego L ^a,e   Cafferata, Eduardo G ^a   Gould, David ^b   Rotondaro, Cecilia ^a   Chernajovsky, Yuti ^b   Curiel, David T ^c,d   Podhajcer, Osvaldo L ^a   Lopez, M Veronica ^a  

^a Leloir Institute CONICET ^*  (Argentina)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c University of Alabama at Birmingham   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSIDAD NACIONAL DE SAN MARTÍN   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ONCOLYTIC ADENOVIRUS; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; FIBROBLAST; HUMAN; HUMAN CELL; HYPOXIA; INFLAMMATION; MALE; MELANOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; STROMA;

EID: 84885951940     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.191     Document Type: Article

References (38)

1. Adriaansen J, Khoury M, de Cortie CJ et al. (2007) Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 66:1143-50 (Pubitemid 47309728)
2. Alemany R (2007) Cancer selective adenoviruses. Mol Aspects Med 28:42-58
3. Bedogni B, Powell MB (2009) Hypoxia, melanocytes and melanoma-survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res 22:166-74
4. Cairns R, Papandreou I, Denko N (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4:61-70
5. Chai L, Liu S, Mao Q et al. (2012) A novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapy. Cancer Gene Ther 19:247-54
6. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
7. Choi J-W, Lee J-S, Kim SW et al. (2012) Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 64:720-9
8. Dent P, Yacoub A, Hamed HA et al. (2010) The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther 128:375-84
9. Garber K (2006) China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 98:298-300
10. Greco O, Marples B, Dachs GU et al. (2002) Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther 9:1403-11 (Pubitemid 35244166)
11. Guo X, Evans TR, Somanath S et al. (2007) In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. Br J Cancer 97:745-54 (Pubitemid 47396284)
12. Hafner M, Zimmermann K, Pottgiesser J et al. (1995) A purine-rich sequence in the human BM-40 gene promoter region is a prerequisite for maximum transcription. Matrix Biol 14:733-41 (Pubitemid 26014660)
13. Hendrix MJC, Seftor EA, Hess AR et al. (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3:411-21 (Pubitemid 37328845)
14. Hodi FS, O'Day SJ, McDermott DF et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-23
15. Hogg RT, Garcia JA, Gerard RD (2010) Adenoviral targeting of gene expression to tumors. Cancer Gene Ther 17:375-86
16. Hsu M-Y, Meier F, Herlyn M (2002) Melanoma development and progression: a conspiracy between tumor and host. Differentiation 70:522-36 (Pubitemid 36194317)
17. Huang X, Jia R, Zhao X et al. (2012) Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. Br J Ophthalmol 96:1331-8
18. Jiang G, Zhang K, Jiang AJ et al. (2012) A conditionally replicating adenovirus carrying interleukin-24 sensitizes melanoma cells to radiotherapy via apoptosis. Mol Oncol 6:383-91
19. Juven-Gershon T, Kadonaga JT (2010) Regulation of gene expression via the core promoter and the basal transcriptional machinery. Dev Biol 339:225-9
20. Khoury M, Adriaansen J, Vervoordeldonk MJ et al. (2007) Inflammationinducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med 9: 596-604 (Pubitemid 47073992)
21. Lee JY, Lee YS, Kim JM et al. (2006) A novel chimeric promoter that is highly responsive to hypoxia and metals. Gene Ther 13:857-68
22. Lee SJ, Kim HS, Yu R et al. (2002) Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther 6:415-21 (Pubitemid 36305345)
23. Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179-85 (Pubitemid 38352453)
24. Liu BH, Wang X, Ma YX et al. (2004) CMV enhancer/human PDGF-beta promoter for neuron-specific transgene expression. Gene Ther 11:52-60 (Pubitemid 38111388)
25. Lopez MV, Viale DL, Cafferata EG et al. (2009) Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS One 4:e5119
26. Melnikova VO, Bar-Eli M (2009) Inflammation and melanoma metastasis. Pigment Cell Melanoma Res 22:257-67
27. Modlich U, Pugh CW, Bicknell R (2000) Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 7:896-902 (Pubitemid 30303587)
28. Podhajcer OL, Benedetti L, Girotti MR et al. (2008) The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 27:691-705
29. Poulsen TT, Pedersen N, Juel H et al. (2008) A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Ther 15:563-75
30. Rivera AA, Davydova J, Schierer S et al. (2004) Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CARnegative melanoma cells. Gene Ther 11:1694-702 (Pubitemid 39591764)
31. Schadendorf D, Algarra SM, Bastholt L et al. (2009) Immunotherapy of distant metastatic disease. Ann Oncol 20(Suppl 6):vi41-50
32. Senzer NN, Kaufman HL, Amatruda T et al. (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763-71
33. Shima DT, Kuroki M, Deutsch U et al. (1996) The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J Biol Chem 271:3877-83
34. Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365:687-701 (Pubitemid 40260892)
35. van Kempen LCLT, Rijntjes J, Mamor-Cornelissen I et al. (2008) Type I collagen expression contributes to angiogenesis and the development of deeply invasive cutaneous melanoma. Int J Cancer 122:1019-29 (Pubitemid 351213999)
36. Vaupel P (2010) Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol 32:125-7
37. Wu XC, Chen VW, Steele B et al. (2003) Cancer incidence in adolescents and young adults in the United States, 1992-1997. J Adolesc Health 32:405-15 (Pubitemid 36627569)
38. Yew NS, Przybylska M, Ziegler RJ et al. (2001) High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 4:75-82 (Pubitemid 32684705)